bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
Software and Biotech Are Eating the World
by Kevin Cook
Technology innovation is accelerating productivity, disruption and wealth creation, but what about valuations?
Is Celgene Set to See Improved Results in the Second Half?
by Zacks Equity Research
After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
by Zacks Equity Research
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights today's trending stories, including the departure of PepsiCo's CEO, Jamie Dimon's latest public wisdom, and Bluebird Bio's new partnership. Later, he recaps recent developments in the T-Mobile-Sprint merger and previews what the combined company might look like.
Why Is Bluebird Bio (BLUE) Stock Gaining Today?
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) gained in morning trading Monday after the company announced a new partnership with Regeneron Pharmaceuticals (REGN). The five-year agreement will see both firms collaborate on new cell therapies for the treatment of cancer.
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.
Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -26.52% and -28.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Humana (HUM) Stock in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second quarter is likely to gain traction from solid individual Medicare Advantage membership growth.
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
Celgene (CELG) Beats Q2 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) reports better-than-expected results for the second-quarter, on the back of growth in Revlimid sales. The company also raises its annual guidance.
Dopamine and the Weather, Part 2
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics???yet.
Celgene Reports Positive Data on Tecentriq, Abraxane Study
by Zacks Equity Research
Celgene (CELG) reports positive results from a late-stage study on the combination of oncology drug, Abraxane, with immuno-oncology drug, Tecentriq, in advanced breast cancer patients.
Celgene, Acceleron Report Positive Data on Thalassemia Drug
by Zacks Equity Research
Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.
Celgene (CELG) Down 21% So Far in 2018: What Lies Ahead?
by Zacks Equity Research
Celgene's (CELG) shares decline 21%, in the year-to-date period, on pipeline setbacks. However, we expect a better performance in the second half.
Celgene Presents Data on CAR T Therapy, Revlimid & Pomalyst
by Zacks Equity Research
Biotech major Celgene presents encouraging data on its oncology drugs Revlimid, Pomalyst along with other experimental therapies at the ASCO.
bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA
by Zacks Equity Research
bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.
Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength
by Zacks Equity Research
Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.
Can Celgene (CELG) Keep Its Earnings Streak Alive in Q1?
by Zacks Equity Research
Celgene (CELG) is likely to maintain momentum in the first quarter on the strength of its lead drug, Revlimid despite recent failures.
Celgene (CELG) President and COO to Step Down: What's Ahead?
by Zacks Equity Research
Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.
Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate
by Zacks Equity Research
Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Why Sarepta (SRPT) Jumped and We Sold
by Kevin Cook
Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
Healthcare Heroes That Aren't Done Yet
by Kevin Cook
Key growth stocks across medical industries tell you the megatrends are in full force for years to come
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio